Multi organ on chip

WO2024242652A1PCT designated stage Publication Date: 2024-11-28IZMIR YUKSEK TEKNOLOJI ENSTITUSU
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/TR2024/050432
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Filing Date
2024-05-02
Publication Date
2024-11-28

Smart Images

  • Figure TR2024050432_28112024_PF_FP_ABST
    Figure TR2024050432_28112024_PF_FP_ABST
Patent Text Reader

Abstract

The invention relates to a multi-organ chip capable of mimicking more than one organ, which can be used to obtain pharmacokinetic, and / or pharmacodynamic and / or cellular and / or molecular and / or structural data.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] MULTI ORGAN ON CHIP

[0002] Technical Field of the Present I nvention

[0003] The invention relates to a multi-organ chip that can mimic more than one organ and can be used to obtain pharmacokinetic, and / or pharmacodynamic and / or cellular and / or molecular data.

[0004] Background of the Present I nvention

[0005] Organ-on-chips (OOC) are microfluidic-based cell culture systems with controlled, dynamic conditions that mimic the micro-physiological environments of organs in the human body. More than one organ can coexist in a multi organ chip (MOC).

[0006] Drugs discovered and developed through traditional drug testing show unexpected toxicity and drug efficacy problems, accounting for approximately 50% of drug development failures, and approximately 23% of drug candidates fail in the final stage of drug development. The failure rate of the entire drug development process is 90% . The most important reason for this is the 2D (dimensional) cell culture systems and animal models used in the pre-clinical stage. 2D cell culture cannot imitate the living 3D environment. It is known that the responses of cells to drugs are different in 2D and 3D culture experiments and that 3D culture results are more compatible with the drug response in vivo. Since animal models do not match human physiology, drugs that work in animal models may not work in humans and vice versa. Animal models cannot answer questions, especially regarding the immune system.

[0007] The use of 3D cell culture in conjunction with MOC offers significant opportunities for drug discovery. However, independent OOC devices that mimic individual organs are insufficient to study drug effects in more than one organ. Although various OOCs have been developed to simulate different organs simultaneously in a single device, they have some problems:

[0008] -Different organs are represented physically on different devices, not on a single device, and they require connection to each other,

[0009] -Requires flow through pump and hose connections between parts representing different organs,

[0010] -The upper parts of the compartments in the devices should be closed, and holes should be used for material entry and exit,

[0011] -Diffusion alone is not enough,

[0012] -Multi-stage production,

[0013] -Production requires combining or gluing different parts,

[0014] -Organs cannot be easily added and removed from the system like modular Lego.

[0015] Brief Description and Purposes of the I nvention

[0016] The present invention is a multi-organ chip (MOC) that allows multiple organs to be represented on a single part. I n this MOC device, cells are located in a three-dimensional environment. The biggest advantage it brings against the problems mentioned above; More than one organ can be imitated or represented together without the need for flow. It also makes production possible in one piece.

[0017] The heart can pump 5 liters of blood per minute, so the blood flowing between organs can be mixed instantly. Therefore, there is no need to connect organs on chips via flow. Therefore, within the scope of the invention, organ volumes (3D cell culture) can be focused on and the blood circulation can be represented through the volume of the cell culture medium. As a result, a flow-free MOC is obtained in scaled chambers coated with cell culture medium, where organs are represented by culturing organspecific cells in a 3D environment in a hydrogel.

[0018] Brief Description of the Technical Drawings

[0019] Figure 1 a: Representative cross-sectional image showing the main parts of the MOC.

[0020] Figure 1 b: Representative cross-sectional image showing the main dimensions of the MOC.

[0021] Figure 1 c: Representative top view showing the main dimensions of the MOC.

[0022] Figure 2: Representative top view showing a circular configuration of the MOC.

[0023] Figure 3: Representative top view showing a sequential configuration of the MOC.

[0024] Figure 4: Representative top view showing another configuration of the MOC.

[0025] Figure 4a: Detail view of Figure 4.

[0026] Figure 5: Representative top view showing the distance between parts of the MOC.

[0027] Figure 6: Representative top view of an MOC with multiple compartments.

[0028] Figure 6a: Sectional view of Figure 6 along the A-A axis. Figure 7a: Cell viability graph depending on doses and time

[0029] Figure 7b: Graph of doxorubicin concentration depending on doses and time

[0030] The parts / parts / elements for the MOC developed with this invention are numbered separately and the explanation of each number is given below. 1 : Partition

[0031] 2: Separator

[0032] 3: Common liquid

[0033] 4: First organ hydrogel part

[0034] 5: Second organ hydrogel part 6: First organ hydrogel height

[0035] 7: Second organ hydrogel height

[0036] 8: Liquid height above the first hydrogel

[0037] 9: Liquid height above the second hydrogel

[0038] 10: Separator size 1 1 : First organ hydrogel width

[0039] 12: Separator width

[0040] 13: Second organ hydrogel width

[0041] 14: First organ hydrogel length

[0042] 15: Second organ hydrogel length 16: Representative first organ

[0043] 17: Representative second organ

[0044] 18: Representative third organ

[0045] 19: Primary distance

[0046] 20: Secondary distance

[0047] 21 : Tertiary distance

[0048] 22: Separator length

[0049] G: Body

[0050] S: Cell culture

[0051] L1 : Split depth

[0052] A: A-A section axis

[0053] Detailed Description of the Present I nvention

[0054] The invention is a multi-organ chip (MOC) that can mimic more than one organ or cell to determine the effectiveness and toxic effects of drugs. Since more than one organ can be represented, the effect of a drug on different organs can be determined.

[0055] Referring to Figures 1 a, 1 b and 1 c; Said multi-organ chip is structured in such a way that more than one cell culture (S) can be filled without directly mixing with each other. Here, cell culture (S) is defined as culturing cells in a hydrogel by providing a 3-dimensional environment with a hydrogel. It is of a size that can contain all compartments (1 ) and parts of the multi-organ chip representing different organs and is preferably a single piece. Accordingly, the relevant chip body (G) contains at least one compartment (1 ) on which the sample can be stored. The body (G) base is preferably the size of a microscope slide or multi-well plate so that it can be placed on the sample tray in microscopes or automatic liquid handling robots or plate readers.

[0056] The material of the multi-organ chip of the invention can be silicon, glass, a metal, a thermoplastic, a thermoset, an elastomer, a paper, a shape memory polymer, an electrospun fiber, a natural or synthetic hydrogel, agarose, agate, a natural or synthetic polysaccharide, a resin for 3D printing, a SU-8, polydimethylsiloxane (PDMS), polycarbonate (PC), polystyrene (PS), polyethylene (PE), a cyclic olefin copolymer (COC), cyclic olefin polymer (COP), polymethylpentene (PMP), poly (1 -trimethylsilyl- 1 -propyne) (PTMSP), (di-phenylacetylene) methylated polymer, Poly (methyl methacrylate) (PMMA), or a combination thereof.

[0057] Said body (G) contains at least one compartment (1 ). However, there is no obstacle to configuring more than one compartment (1 ) on the same body (G) . I n the explanations below, definitions will be made on a compartment (1 ), but in case more than one compartment (1 ) is used, the relevant explanations are valid for the relevant compartments, fully or partially.

[0058] I n the invention, since two organs are represented, there is a compartment

[0059] (1 ), a separator (2) and two parts where different cultures separated in the compartment (1 ) are located thanks to this separator (2) . The said separator

[0060] (2) does not have to divide the compartment into parts of equal volumes or equal geometries. I n case more than one separator (2) is used, the separator lengths (10) of the said separator do not have to be equal. The position or length of the separator (2) can be changed depending on the portion volumes to be obtained. Therefore, while the parts separated by the separator (2) and located within the compartment ( 1 ) include different cell or organ cultures; The compartment includes both the cell cultures (S) contained in the parts and the common liquid (3) , which is the cell culture medium and may contain agents, as a total volume. When any agent is added to the common fluid (3) in the said multi-organ chip, this agent can interact with all organs. For example, if this agent is a drug that is metabolized in the liver, the metabolites of this drug can also reach other organs through the common fluid (3).

[0061] Preferably, the said compartment (1 ) is in prismatic form, but it can also be configured in cylindrical, elliptical and similar geometries. Said chamber may also have an irregular geometry that can retain a fluid or semi-fluid sample or cell culture.

[0062] There may be a separator within the compartment that prevents different contents from mixing with each other and divides the compartment (1 ) into parts, but the height of this separator ( 10) is higher than the height of the parts where they are positioned in a way to prevent the mixing of different contents and at the same time, the compartment (1 ) is designed to prevent the mixing of the common liquid (3). can be found to be lower than its height.

[0063] More precisely, within the said compartment (1 ), preferably the compartment is divided into at least two parts by means of a separator (2) in the form of a wall perpendicular or inclined to the ground. Here, the separator (2) is configured in a way that does not allow direct fluid passage between the two parts unless the compartment (1 ) is filled with more fluid than its own size and cell culture (S). Preferably, the separator (2) is arranged continuously between the two walls and / or edges of the compartment. The two parts mentioned do not have to be of equal volume and / or identical geometry. Since different organ cultures (S) are proportioned considering the sizes of the organs in the multi-organ test, it may be preferable for the word separator (2) to divide the compartment volume unequally.

[0064] The length ( 10) of the said separator is shorter than the length (L1 ) of the section in question. The size difference here is that after filling the cell culture (S) into the sections, the rest of the compartment is filled with the common liquid (3), ensuring that the liquid (3) in question comes into contact with the cell culture (S) in both sections.

[0065] Organ compartments may be at different distances from each other because the depth of the single-piece multi-organ chip in the part to which liquid will be added is sufficient to cover all organ compartments. Thus, in the multiorgan chip, the culture medium or blood-like fluid to be added to represent blood can cover all organ compartments. At the same time, the total fluid height of the different cell cultures and the liquid added on top of them (3) does not exceed the height of the compartment.

[0066] Preferably, said compartment (1 ) contains at least one opening to allow the filling of at least two cell cultures (S). Alternatively, the compartment ( 1 ) is provided in a completely closed volume, and the user can fill the cell culture (S) or liquid (3) in question into the relevant parts of the compartment (1 ) through an opening he creates at the time of use.

[0067] Referring to Figure 1 b; The first organ hydrogel length (6) refers to the length of the first organ hydrogel part (4) filled into the first part, not exceeding the compartment length (L1 ). Similarly, the length of the second organ hydrogel in the other part (7) refers to the length of the second organ hydrogel part (7) filled in the second part. Here, the lengths of the hydrogel parts filled into two parts do not have to be equal. Accordingly, the height of the liquid over the first hydrogel (8) above the first part and the height of the liquid over the second hydrogel (9) above the second part do not have to be equal.

[0068] Referring to Figure 1 c; The geometries of the parts provided on the said compartment ( 1 ) may differ from each other. As can be seen in Figure 2b, the first organ hydrogel width (1 1 ) and the second organ hydrogel width (13), the first organ hydrogel length ( 14) and the second organ hydrogel length are different from each other.

[0069] Referring to Figure 2; Said multi-organ chip may contain more than two parts, and for this reason, a compartment (1 ) is divided into parts by means of more than one separator (2) . I n Figure 2, the representative first organ (16), the representative second organ (17) and the representative third organ (18) are shown, and sections can be created for more organs. Here, the parts containing the representative first organ (16), the representative second organ (17) and the representative third organ (18) together form a compartment ( 1 ) and these parts are separated from each other by separators (2).

[0070] I n a preferred embodiment, each said part is separated from at least two other parts by a separator (2) and preferably forms a circular structure. Although three sections are shown in Figure 2, the circular structure can be formed with a greater number of sections and separators (2).

[0071] Referring to Figure 3; Unlike the one in Figure 2, it is also possible to separate the said compartment (1 ) sequentially, that is, the first and last parts, respectively, from the next and previous parts only by means of a separator (2) .

[0072] Referring to Figures 4 and 4a; The said separator (2) has a separator width (12) and a separator length (22) as well as the separator length (10). The length of said separator (22) does not have to be equal to the length of one side of the formed part (if any).

[0073] Preferably, said compartment length (L1 ), separator length (10), separator width (12) and a separator length (22) vary between 1 -130 mm. Similarly, organ hydrogel lengths and liquid heights over the hydrogel in the mentioned parts vary between 1 -130 mm.

[0074] Referring to Figure 5; The first distance ( 19) between the center points of said first representative organ (16) and the second representative organ (16), the second distance (20) between the center points of said first representative organ (16) and the third representative organ (18), the second distance (20) between the center points of said second representative organ (16), There is a third distance (18) between (17) and the center points of the third representative body (18).

[0075] Referring to Figures 6 and 6a; I n an embodiment of the invention, there are multiple sections separated from each other by a separator (2) on the said body (G). Here, multiple comparisons for different organs can be made on a single MOG.

[0076] I n the preferred embodiment of the invention, MOC (multi organ chip) design and production. I n MOC, the liver and breast are designed side by side to allow the diffusion of chemicals and molecules to achieve organ communication. The size of the liver part of the MOC is 0.4 mm (height) , 6.99 mm (width) and 10 mm (length), and the size of the breast part of the MOC is 0.4 mm (height), 3.2125 mm (width) and 10 mm (length) can be. Otherwise the liver can be 0.4mm (height), 8.36mm (width) and 8.36mm (length), 0.4mm (height), 5.7mm (width) and 5.7mm (length) , in this case, when looking at the cross section, the square shape can provide more homogeneous diffusion. Sections can be hexagons, pentagons, circles, ellipses, etc. instead of squares, available. Both the liver and breast compartments are kept at equal height so that they have the same hydrogel thickness suitable for imaging under a light microscope. The MOC is opentopped and does not need to be attached to a microscopic slide. To create an easy connection between the breast and liver sections, the medium is added on top of the cell culture (S) as the common liquid (3). Diffusion may facilitate organ interactions. The cell culture (S)-common fluid (3) interface enables molecular communication between breast and liver cells and the delivery of the drug metabolized in liver cells to breast cells. With dead-live cell dyes, cell viability can be determined by spectroscopic reading or fluorescence imaging.

[0077] I n one embodiment of the invention, breast and liver organs are represented. Organs are represented using reduced volume values on a scale of 1 : 1000 or 1 : 100000 of their volume in the body. For example, at the 1 :50000 reduction scale, the breast organ is represented by a volume of 13 microliters for an average volume of 643 milliliters, and the liver organ is represented by a volume of 28 microliters for an average volume of 1398 milliliters. The blood volume is used as 104 microliters. Since blood circulation occurs in the body at a rate of approximately 5 L / min, there is no need to use flow in OOC. Sections where cells from different organs will be placed are created on a single piece, and the volumes of these sections are prepared in accordance with the reduction scale. Such as 13 microliters and 28 microliters in the breast-liver and 1 :50000 scale sample. The dimensions of the breast compartment are 0.4 millimeters in depth, the width and length are equal and 5.7 millimeters, the dimensions of the liver compartment are 0.4 millimeters in depth, the width and length are equal and 8.36 millimeters. Depth, width and length values vary for different organs. The depth can be between 0.05 and 5 millimeters. Having equal width and length is advantageous for diffusion in depth. Width and length can be between 0.01 and 100 millimeters.

[0078] I n the preferred embodiment of the above-mentioned invention, only two organs are represented. Each organ can be found in the system with a compartment of appropriate size according to the reduction rate. When the average weight in women is 60 kg, the equivalent with a 1 :50000 reduction is 1200 microliters. 104 microliters of this is blood volume. A compartment containing cell-free hydrogel can also be used in an alternative application of the invention for the volume remaining outside each organ compartment to be added to the system. For example, a compartment of 1200-104-13- 28= 1055 microliters can be added as an alternative to the application studied above. The common liquid volume (3) to be used can also be determined independently of the reduction ratio, for example 1 milliliter can be used instead of 104 microliters in the example above.

[0079] Doxorubicin® causes side effects in the heart organ. Therefore, a breastliver-heart triple system can be used in an alternative embodiment of the invention. Various organ volumes for women for 60 kg weight and 1 :50000 scale are as follows: Heart 4.8, lung 27, brain 25, kidney 5.2, bone 44, fat 400, pancreas 1.6, spleen 2.8, skin 40, red marrow 17.4, yellow marrow 40, thyroid 0.34, digestive system organs 21.8, poorly perfused organs 500 microliters. I n addition, alternative multi-organ chips can be designed according to the total weight and organ weights of male or child individuals. For cells representing that organ in each organ compartment, organ-specific cells as well as organ-specific or general endothelial cells can be added mixed with other cells or as a layer on top of the compartment. Cells are mixed with a hydrogel and added to the relevant compartments. I n order for the hydrogel to adhere to the MOC surface, the MOC surface can be coated with APTES, poly-lysine or similar chemicals. I n addition, the MOC surface can be covered with collagen, fibronectin, laminin and similar proteins. I n experiments with MOC, different doses of drugs can be tested. The data obtained by determining cell viability by spectroscopy or microscopy and the amounts of drugs and / or metabolites by HPLC can be used in pharmacokinetic and pharmacodynamic modeling.

[0080] For example, cell viability in different organ parts can be determined by calcein AM staining. Additionally, whole cell count and dead cell count can be determined with Hoechst and propidium iodide. Cell viability can be determined in all organs by spectroscopic measurements with Alamar blue dye. I n addition, cell viability in different organs can be determined by numerical analysis by viewing the fluorescent signal under the microscope with Alamar blue dye.

[0081] With the multi-organ chip (MOC) defined in the invention, the effects of an agent on more than one organ can be examined simultaneously. This agent may include, but is not limited to, an anti-cancer drug, an antibiotic, a growth factor, an antibody, a biosimilar, a hormone, a vitamin, culture medium, blood, serum, physiological buffer solution, biological or chemical molecule, growth factor. , protein, enzyme, peptide, DNA molecule, RNA molecule, lipid molecule, sugar molecule, carbohydrate, amino acid, soluble or hydrogelbound agent, nanoparticle, micelle, a microbubble, a salt, an acid or a base, a biochemical -stimulus can be temperature or a combination of these. An agent may also be a cell because cells can take an active role or produce a particular effect, where an agent may include, but is not limited to, a bacterium, archaea, eukaryote, yeast, fungus, plant cell, epithelial tissue cell, a connective tissue cell, a muscle tissue cell, a nerve tissue cell, a cancer cell, an immune cell, a blood cell, a neuron, a cell line cell, a biopsy cell, a spheroid, an organoid, or a combination thereof. Cell agents may also be a plant seed, an embryo, a tissue or a synthetic tissue that can be isolated from an organism such as a mouse, an organ or a synthetic organ that can be isolated from an organism such as a mouse, a biopsy sample, a blood sample, or a combination thereof. The agent may also be products of the cells, including, but not limited to, an exosome, a cytokine, a growth factor, a metabolite, a waste product, or a combination thereof.

[0082] MOC mentioned in the invention; It can be produced by 3D printing, UV lithography, electron beam lithography, ion beam lithography, hot embossing, microinjection molding, injection molding, xurography, or a combination of these. The MOC itself or its parts can be lego-like, meaning that parts can be assembled from existing parts such as but not limited to compartments / partitions, walls. Parts may be joined by methods including, but not limited to, PSA bonding, chemical bonding, permanent bonding, temporary bonding, electrostatic bonding, hot bonding, UV / ozone treatment, plasma bonding, or a combination thereof.

[0083] A hydrogel can be used to provide a 2.5D and / or 3D environment in MOC. Cell agents can be embedded or embedded in a hydrogel. Extracellular agents can be incorporated into a hydrogel. The cell-containing hydrogel can be placed into compartments by bioprinting. The hydrogel located in the chamber volume and used to create a microenvironment can be a hydrogel containing a polymer and / or copolymer in a structure that allows diffusion. The hydrogel to be used in the multi-organ chip described here; natural matrices such as matrigel, synthetic matrices such as collagen, laminin, gelatin, agarose, agar, puramatrix, biogelx, natural or synthetic polysaccharide, polylactic acid, polyglycolic acid, poly(lysine), polyanhydride; poly(lactide-co-glycolide) (PLGA) polymer, a polyamino acid, a poly(alkylene oxide), a poly(ethylene oxide), a poly(allylamine) (PAM), a poly(acrylate) , polyester, polyhydroxybutyrate and poly-epsilon-caprolactone, polyphosphazine, poly(vinyl alcohol) , a modified styrene polymer, poly (4- aminomethylstyrene) , pluronic polyol, 30 polyoxamers, poly (uronic acid), poly (vinylpyrrolidone), containing one or more of these It may be a copolymer.

[0084] The multi-organ chip that is the subject of the invention can be used in methods of simultaneously examining and / or testing the effects of a biological or chemical agent on more than one organ.

[0085] The term biological agent used herein refers to a substance derived from a living organism or its products used in the prevention, diagnosis or treatment of diseases.

[0086] This method begins with the provision of a multi-organ chip (MOC) with the above-mentioned features, and by placing cell cultures (S) belonging to different organs or different cells in the sections separated by a separator inside the compartments, at least one of these cell cultures contains at least one biological or other organism to be tested, the presence of a chemical or at least one biological or chemical to be tested in the common liquid volume (3) , waiting for a certain period of time for diffusion to occur in the MOC, and then the cells in the cell cultures (S) and / or the hydrogel and / or the common liquid (3). It includes the steps of analyzing cellular (such as cell viability, cell death) and / or molecular (such as DNA, RNA and protein expressions) and / or chemical (such as drug concentration, metabolite concentration) and / or structural (such as degradation of hydrogel by cells) changes. As a result of this analysis, the effect of the agent or a drug used on more than one cell culture (S) is determined. MOC, which does not contain any agent or drug, is used as the control group.

[0087] I n an embodiment of the invention, by performing the method on more than one equivalent MOC for analysis and examination (for example, a drug is used in one MOC but not in the other), the effect can be determined through the relationship between these two processes.

[0088] For example, as can be seen in Figures 7a and 7b, these determinations can be monitored through cell viability and / or Dox concentration.

[0089] The important point here is that while the cultures are positioned in sections, the hydrogel containing the cells should be positioned in a way that does not exceed the height of the separator that divides the compartment into sections, and then, while filling the cultures on the cultures positioned appropriately in the sections, the height of the common liquid (3) should be filled in a way that does not exceed the length of the compartment.

[0090] I n a preferred embodiment of the invention, the amount of diffusion in the system is also controlled by the amount of filling of the cell cultures (S) and the common liquid (3) into the sections / compartments for the said analysis or examination and, accordingly, by changing the organ hydrogel width, length and height in the sections and the liquid heights on the hydrogel, can be done.

Claims

CLAI MS1 ) A multi-organ chip for testing the effects of a biological or chemical agent on more than one organ at the same time wherein the said multi-organ chip comprises i. at least one compartment (1 ),II. at least one separator (2) that divides the said compartment (1 ) into at least two parts and whose separator length (12) is shorter than the length of the compartment length (L1 )2) A multi-organ chip as set forth in claim 1 , wherein the said multi-organ chip is monolithic.3) A multi-organ chip as set forth in claim 1 , wherein the said multi-organ chip contains at least one opening that allows fluid to be filled into the compartment (1 ).4) A multi-organ chip as set forth in claim 1 , wherein the said opening is provided on the compartment (1 ).5) A multi-organ chip as set forth in claim 1 , wherein the ceiling of the said compartment (1 ) is completely open.6) A multi-organ chip as set forth in claim 1 , wherein the said multi-organ chip contains more than one separator (2) and more than two parts.7) A multi-organ chip as set forth in claim 6, wherein the said parts are arranged sequentially.8) A multi-organ chip as set forth in claim 6, wherein at least one of the said parts is separated from the other part with a separator (2).9) A multi-organ chip as set forth in claim 8, wherein the said parts are arranged in a circular manner.10) A multi-organ chip conforming to any of the above claims wherein the said multi-organ chip contains more than one compartment (1 ).11 ) A multi-organ chip as set forth in claim 1 , wherein the said compartment (1 ) is fabricated using silicone, glass, metal, thermoplastic, thermoset, elastomer, paper, memory polymer, electrospun fiber, natural or synthetic hydrogel, agarose, agate, natural or synthetic polysaccharide, resin, SU-8, polydimethylsiloxane (PDMS), polycarbonate (PC) , polystyrene (PS), polyethylene (PE), cyclic olefin copolymer (COC) , cyclic olefin polymer (COP), polymethylpentene (PMP), poly ( 1 -trimethylsilyl-1 -propyne) (PTMSP), (di - phenylacetylene) methylated polymer, Poly (methyl methacrylate) (PMMA) or a combination thereof.12) A method for simultaneously examining and / or testing the effects of a biological or chemical agent or a cell on more than one organ wherein said method comprises the steps of a. Providing a multi-organ chip in accordance with any of the claims 1 -11 , positioning different cell cultures (S) in at least two of the said parts in a way that does not exceed the length (10) of the separator (2), b. Filling the said compartment (1 ) with a common liquid (3) containing at least one biological or chemical agent, c. Analyzing changes in the cells in the cell culture (S) exposed to diffusion and / or the hydrogel and / or the common fluid (3).13) A method as set forth in Claim 12, wherein the width, length and height of the said cell culture (S) is selected according to the desired diffusionamount.14) A method as set forth in Claim 12, wherein the said analysis results are compared with at least one control group.15) A method as set forth in Claim 14, wherein the said the multi-organ chip as the control group does not contain biological or chemical agents.16) A method as set forth in Claim 14, wherein the said cell culture (S) in the multi-organ chip as the control group contains a cell-free hydrogel.17) A method as set forth in Claim 12, wherein the changes are cellular, molecular, chemical and / or structural.